New study confirms that E171 is essential for pharmaceuticals

A team of more than 20 scientists from leading European and US universities have recently reviewed the functions and uses of the specialised titanium dioxide material (E171) used in the manufacture of pharmaceuticals.

Titanium dioxide is essential in pharmaceuticals

Scientists have confirmed that E171 performs unique and essential functions in pharmaceuticals, from the protection of active ingredients, to improving patient acceptability, helping to make medicines safe to use and combating counterfeiting.

The study also highlights that, after a thorough assessment of potential alternative materials, at present, there are no available alternatives that can replace E171 and its critical role in pharmaceuticals.

The Titanium Dioxide Manufacturers Association (TDMA) welcomes these findings.

In September 2021, the European Medicines Agency (EMA) concluded that replacing E171 in medicines would have a negative impact on the quality and quantity of medicines in the EU. See full TDMA’s statement on the EMA opinion.

E171 continues to be authorised in pharmaceuticals in the EU.